News releases

Biosimilars Canada is pleased to announce the unanimous election of Mr. Mike Woolcock, Senior Vice President of the Apobiologix division of Apotex, as Chair of the Biosimilars Canada Board. Mr. Mike Casia, President and Managing Director of Organon Canada, has been unanimously elected as Vice-Chair of the Biosimilars Canada Board.

Biosimilars Canada, a national association representing Canada’s biosimilar medicines industry, today welcomed the announcement by Ontario Health Minister Sylvia Jones that the province will implement a “switching” or transitioning policy to expand the use of biosimilar biologic medicines for the Ontario Drug Benefit (ODB) program in 2023.

There are few solutions to such healthcare challenges that allow governments to provide more value to taxpayers for the same dollars. But that is precisely the value proposition provided through the expanded use of biosimilar medicines.

Toronto – October 20, 2022 – Biosimilars Canada, a national association representing Canada’s biosimilar medicines industry, today welcomed the announcement by the Government of Saskatchewan that it will implement a “switching” or transitioning policy to expand the use of biosimilar...

Biosimilars Canada hosted a press conference at Queen’s Park, calling on the government of Premier Doug Ford to implement a biosimilars switching policy.

Biosimilars Canada welcomes the announcement by the Government of Nova Scotia that it will implement a “switching” or transitioning policy to expand the use of biosimilar medicines under its public drug programs.